Insulet Corporation which can be found using ticker (PODD) now have 17 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 395 and 329 and has a mean target at $354.29. Given that the stocks previous close was at $288.34 this would imply there is now a potential upside of 22.9%. It’s also worth noting that there is a 50 day moving average of $299.44 while the 200 day moving average is $288.88. The company has a market cap of 19.75B. The stock price for the company is currently 283.43 USD
The potential market cap would be $24,272,046,842 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of Infinity, revenue per share of 19.7 and a 1.51% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
